Tactiva, Inc. Email Format
BiotechnologyNew York, United States2-10 Employees
Tactiva, Inc. is a small biotechnology research company based in Buffalo, New York, focused on cancer immunotherapy. It develops adoptive T cell therapies employing a dual T cell receptor approach to reprogram a patient's own T cells to recognize and destroy cancer cells. The technology is licensed from Roswell Park Cancer Institute, situating the program within the broader immuno-oncology field. As a development-stage company, Tactiva's work centers on next-generation autologous cellular immunotherapies and early preclinical activity. Public disclosures from 2017 reference plans to present preclinical data on its autologous cellular immunotherapy program, underscoring ongoing development in Buffalo.